pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›REGADENOSON
drug
save

REGADENOSON

updated 3mo ago
by APOTEX
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying REGADENOSON

  • N/AThe MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPIcompletedn=20
  • phase2A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patientsrecruitingn=54
  • —Use of Stress-CMR Using Regadenoson and GE-267 in Adult Patients with Known or Suspected Coronary Artery Diseasenot yet recruitingn=80
  • phase1Regadenoson R-T Perfusion Imaging Trialcompletedn=100
  • phase2A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)completedn=124
  • phase3Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)completedn=347
  • phase3Regadenoson Real Time Perfusion Imaging Trial-Optisoncompletedn=50
  • phase4Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Trackingcompletedn=161
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Feb 2, 2027
162 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (2)

  • Feb 2, 2027compositionUS 8106183162d
  • Feb 2, 2027formulationUS RE47301162d

News(0)

no news has mentioned this drug yet

brand
REGADENOSON
generic
REGADENOSON
Data sources
ClinicalTrials.gov
last refreshed 17m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?